喹硫平与阿立哌唑治疗血管性痴呆伴发精神行为症状对照研究

目的探讨喹硫平与阿立哌唑治疗血管性痴呆伴发精神行为症状患者的临床疗效和安全性。方法将67例血管性痴呆伴发精神行为症状患者分为两组，分别口服喹硫平和阿立哌唑治疗，观察12周。采用痴呆病理行为评定量表评定临床疗效，副反应量表评定不良反应。结果喹硫平组治疗2周、4周末痴呆病理行为评定量表评分显著低于阿立哌唑组（P〈0．05或0．01）；治疗12周末，喹硫平组显效率为54．8％、有效率为83．9％，阿立哌唑组分别为55．2％、79．3％，两组比较差异均无显著性（x2=0．00、0．17，P〉O．05）。两组不良反应均轻微，发生率比较差异无显著性（P〉O．05）。结论喹硫平与阿立哌唑治疗血管性痴呆伴发精神行为症状患者疗效显著且相当，安全性高，但喹硫平起效更快。

A control study of quetiapine vs. aripiprazole in the treatment of behavioral and psychological symptoms of vascular dementia

Objective To explore the efficacy and safety of quetiapine vs. aripiprazole in the treatment of behavioral and psychological symptoms （BPS） of vascular dementia （VD）. Methods Sixty-seven VD patients with BPS were divided into two groups taking orally quetiapine or aripiprazole for 12 weeks. Efficacies were assessed with the Behavioral Pathology in Alzhei- meres Disease Rating Scale （BEHAVE-AD） and adverse reactions with the Treatment Emergent Symptom Scale （TESS）. Results At the end of the 2nd and 4th week the BEHAVE-AD scores were significantly lower in quetiap- ine than aripiprazole group （P〈0.05 or 0.01） ~ at the end of the 12th week obvious effective and effective rate were respectively 54.8% and 83.9% in quetiapine and 55.2% and 79.3% in aripiprazole group, which showed no sig- nificant differences （x2=0. 00,0. 17,P〈0. 05）. Adverse reactions of both groups were mild and their incidences had no significant differences （P〈0.05）. Conclusion Both quetiapine and aripiprazole have an evident effect and higher safety in the treatment of behavioral and psychological symptoms of vascular dementia, but the former takes effect more rapidly.